Compare URI & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URI | TAK |
|---|---|---|
| Founded | 1997 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0B | 43.3B |
| IPO Year | 1997 | N/A |
| Metric | URI | TAK |
|---|---|---|
| Price | $912.67 | $16.18 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $987.83 | N/A |
| AVG Volume (30 Days) | 555.3K | ★ 2.6M |
| Earning Date | 01-28-2026 | 01-29-2026 |
| Dividend Yield | 0.78% | ★ 3.27% |
| EPS Growth | ★ 1.51 | N/A |
| EPS | ★ 38.83 | 0.14 |
| Revenue | $15,986,000,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $6.18 | N/A |
| Revenue Next Year | $6.13 | $0.47 |
| P/E Ratio | ★ $23.72 | $115.98 |
| Revenue Growth | ★ 6.73 | N/A |
| 52 Week Low | $525.91 | $12.80 |
| 52 Week High | $1,021.47 | $16.48 |
| Indicator | URI | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 60.63 | 64.80 |
| Support Level | $914.04 | $15.87 |
| Resistance Level | $955.00 | $16.48 |
| Average True Range (ATR) | 24.18 | 0.21 |
| MACD | 4.61 | -0.01 |
| Stochastic Oscillator | 71.23 | 70.50 |
United Rentals is the world's largest equipment rental company, principally operating in the US and Canada. It has 16% share in a highly fragmented market serving general industrial (49%), commercial construction (46%), and residential construction (5%). The company operates a $21 billion fleet of equipment, including aerial platforms, forklifts, excavators, trucks, power generators, and various other materials serving local and national accounts from nearly 1,600 locations in North America and 100 abroad. It has pursued a strategy of bundling specialty rental capabilities to offer its customers more advanced solutions in addition to its core equipment rental business, supporting its ambitions to become a one-stop shop for customers and enhance and maintain its margin profile.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.